Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 3/2016

01-03-2016 | Original Scientific Report

Genotype–Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma

Authors: Sendhil Rajan, Ghazala Zaidi, Gaurav Agarwal, Anjali Mishra, Amit Agarwal, Saroj Kanta Mishra, Eesh Bhatia

Published in: World Journal of Surgery | Issue 3/2016

Login to get access

Abstract

Introduction

Pheochromocytoma (PCC) manifests in up to 50 % of MEN2 patients. We correlated the clinico-pathological features of MEN2-associated PCC (MEN-PCC) with RET mutations and compared them with non-MEN adrenal-PCCs.

Methods

In this retrospective single institution study on a large PCC database (n = 208, 1997–2014) 24 MEN-PCC patients with known RET mutations were reviewed. Excluding 7 with incomplete data, the study cohort of 17 MEN-PCC patients from 11 kindreds (M:F::7:10) was identified. Clinical, biochemical, pathological attributes, and outcomes in the MEN-PCC group were correlated with the genotype, and further compared with non-MEN, apparently sporadic adrenal-PCCs (n = 132, excluding 37 extra-adrenal and 15 VHL/NF1/SDH-associated PCC).

Results

Components of MEN2 encountered included MTC in 13(76.5 %), Marfanoid habitus in 2, and PHPT, cutaneous lichen amyloidosis and mucosal neuromas in 1 patient each. In 11(64.7 %), PCC was the first detected MEN2 component (Symptomatic:8, Incidentaloma:3). Four (23.5 %) were normotensive; 8(47.1 %) had bilateral PCC (7 synchronous, 1 metachronous). Surgery for PCC included laparoscopic adrenalectomy in 12; and cortical-sparing adrenalectomy in 2 of 8 bilateral PCC patients. Mean MEN-PCC tumor size was 6.9 ± 3.9 cm, and 6(35 %) had additional adrenal medullary hyperplasia. Four different genotypes were encountered, commonest involving codon 634, others being 804 and 918. Mean age in MEN-PCC (27.7 ± 12.2 years) was lower than non-MEN PCC (39.4 ± 15.7, p = 0.018). Proportion of pediatric patients (35.3 % in MEN-PCC vs. 12.9 % in non-MEN-PCC, p = 0.007), bilateral tumors (47.1 % in MEN-PCC, 4.5 % in non-MEN-PCC, p < 0.001), and adrenal medullary hyperplasia (35.2 % in MEN-PCC, 0.7 % in non-MEN-PCC, p < 0.001) were different. Median 24-hour urinary metanephrines was significantly higher in index MEN-PCC patients, than non-MEN-PCC (634 vs. 214 mcg/24 h, p value = 0.006), but was non-significantly higher in non-index MEN-PCC patients. Mean tumor sizes were comparable in the two groups. None of MEN-PCC patients had malignant PCC, compared to 7(5.3 %) in non-MEN-PCC.

Conclusions

In this cohort of MEN-PCC from India, the commonest causative RET mutations for MEN-PCC involved codon 634. MEN-PCC patients were younger, and more frequently had bilateral PCC than non-MEN disease. MEN-PCC patients in India are diagnosed with large tumors and extremely high catecholamine/metanephrine levels.
Literature
1.
Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24(4):539–553CrossRefPubMed
2.
Agarwal G, Sadacharan D, Aggarwal V et al (2012) Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series. Langenbecks Arch Surg. 397(7):1109–1116CrossRefPubMed
3.
Mannelli M, Castellano M, Schiavi F et al (2009) Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 94:1541–1547CrossRefPubMed
4.
Fishbein L, Merrill S, Fraker DL et al (2013) Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 20(5):1444–1450PubMedCentralCrossRefPubMed
5.
6.
Neumann HP, Bausch B, McWhinney SR (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459–1466CrossRefPubMed
7.
8.
Berndt I, Reuter M, Saller B et al (1998) A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocr Metab. 83:770–774PubMed
9.
Zhou Y, Zhao Y, Cui B et al (2007) RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B. Clin Endocrinol (Oxf). 67(4):570–576PubMed
10.
Ceccherini I, Hofstra RM, Luo Y, et al. (1994) DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 9(10):3025–3029. (Erratum in: Oncogene 1995 10(6):1257)
11.
Margraf RL, Crockett DK, Krautscheid P et al (2009) The Multiple Endocrine Neoplasia type 2 RET proto-oncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 30(4):548–556CrossRefPubMed
12.
Stenson PD, Mort M, Ball EV et al (2014) The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133:1–9PubMedCentralCrossRefPubMed
13.
Pemberton TJ, Mehta NU, Witonsky D et al (2008) Prevalence of common disease-associated variants in Asian Indians. BMC Genet 4(9):13CrossRef
14.
Bayraktar S, Jackson M, Gutierrez-Barrera AM et al (2015) Genotype–phenotype correlations by ethnicity and mutation location in BRCA mutation carriers. Breast J 21(3):260–267CrossRefPubMed
15.
Sharma BP, Saranath D (2011) RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients. J Biosci 36(4):603–611CrossRefPubMed
16.
Alvandi E, Akrami SM, Chiani M et al (2011) Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Thyroid 21(4):373–382CrossRefPubMed
17.
Qi XP, Zhao JQ, Du ZF et al (2013) Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China. Eur J Surg Oncol 39(9):1007–1012CrossRefPubMed
18.
Imai T, Uchino S, Okamoto T et al (2013) High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur J Endocrinol 168(5):683–687CrossRefPubMed
19.
20.
21.
Kim JH, Seong MW, Lee KE et al (2014) Germline mutations and genotype–phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea. Clin Genet 86(5):482–486CrossRefPubMed
22.
Pai R, Ebenazer A, Paul MJ et al (2015) Mutations seen among patients with pheochromocytoma and paraganglioma at a referral center from India. Horm Metab Res 47(2):133–137PubMed
23.
Ganesh HK, Acharya SV, Goerge J et al (2009) Pheochromocytoma in children and adolescents. Indian J Pediatr 76(11):1151–1153CrossRefPubMed
24.
Mishra A, Mehrotra PK, Agarwal G et al (2014) Pediatric and adolescent pheochromocytoma: clinical presentation and outcome of surgery. Indian Pediatr 51(4):299–302CrossRefPubMed
25.
Eisenhofer G, Lenders JW, Timmers H et al (2011) Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 57(3):411–420PubMedCentralCrossRefPubMed
26.
van Berkel A, Lenders JW, Timmers HJ (2014) Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol 170(3):R109–R119CrossRefPubMed
27.
28.
Korpershoek E, Petri BJ, Post E et al (2014) Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome. Neoplasia 16(10):868–873PubMedCentralCrossRefPubMed
Metadata
Title
Genotype–Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma
Authors
Sendhil Rajan
Ghazala Zaidi
Gaurav Agarwal
Anjali Mishra
Amit Agarwal
Saroj Kanta Mishra
Eesh Bhatia
Publication date
01-03-2016
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 3/2016
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-015-3255-6

Other articles of this Issue 3/2016

World Journal of Surgery 3/2016 Go to the issue

Original Scientific Report

Characteristics of Persistent Hyperparathyroidism After Renal Transplantation

Original Scientific Report

Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study

Original Scientific Report

Natural History of Asymptomatic Papillary Thyroid Microcarcinoma: Time-Dependent Changes in Calcification and Vascularity During Active Surveillance

Original Scientific Report

Prognosis After Brain Metastasis from Differentiated Thyroid Carcinoma

Reply, Letter to the Editor

The Prediction of Sonographic features and BRAF Mutation for Central Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: Reply

Original Scientific Report

FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization